

# RIQAS

## THERAPEUTIC DRUGS PROGRAMME

### RQ9111

Lab. Reference Number

Please tick the correct option:

This is a new registration for Therapeutic Drugs

☐

This is an update to an existing Therapeutic Drugs registration

☐

If you wish to register multiple instruments, please complete separate enrolment documents for each instrument

On each document please state an instrument identification name here

#### Instrument Group Reports

Instrument group reports can be provided on request. Please contact RIQAS or your local Randox office or distributor for more details.

#### Inter-Laboratory Group Reports

To receive inter-laboratory group reports, please contact RIQAS directly.

Please indicate cycles required in boxes below

Cycle 73    September 2025 - February 2026

☐

Cycle 74    March 2026 - August 2026

☐

Cycle 75    September 2026 - February 2027

☐

Cycle 76    March 2027 - August 2027

☐

Primary Contact Details: (**CAPITAL LETTERS ONLY**)

QA Officer

Laboratory / Hospital Name

Department

Postal Address

City

State

Postal / Zip Code

Country

Telephone Number

Randox Office / Distributor

## RIQAS THERAPEUTIC DRUGS PROGRAMME

### RIQASNet - ELECTRONIC CORRESPONDENCE

Participation on RIQAS requires access to RIQASNet, a web-based online method for result entry, viewing of released reports and addition or change of assay details. In addition, PDF reports can be e-mailed to up to 3 e-mail addresses. Internet access and login details are required for RIQASNet. A login will be supplied by RIQAS based on "e-mail address 1" below. It is also possible to receive a csv file containing the information found on the summary page of the routine report.

I wish to receive a summary csv file ☐  
(csv files must be sent to the same email addresses as the PDF reports)

**FOR RIQAS USE ONLY**

RIQASNet No

Date added:

By:

PDF copies set to  
csv copies set to**Primary Contact email for RIQASNet/PDF reports/summary csv files (Please write in capital letters only)**

E-mail address 1:

**E-mail addresses for additional PDF reports/summary csv files**

E-mail address 2:

E-mail address 3:

**Customer Declaration:** By submitting this enrolment document to RIQAS, either directly or via my local Randox representative, I, (the customer of RIQAS) confirm that:

- 1) I have read and understood the RIQAS policies stated in the most recent Method Questionnaire associated with this programme.
- 2) I understand that the submission of this enrolment document to RIQAS marks the beginning of an on-going agreement, and I will be automatically enrolled in subsequent cycles of this programme until RIQAS receives written confirmation of my cancellation. This should be received by RIQAS 12 weeks prior to the month in which the cycle starts.
- 3) I understand that I must inform RIQAS of any changes to my contact details, assay details or contract status
- 4) I authorise Randox Laboratories Ltd. to send communication related to the products and service provided to the e-mail or postal addresses stated on this document
- 5) I understand that I am permitted to request disclosure of, change or erase personal details held by Randox Laboratories Ltd. at any time.

## REGISTRATION OF ASSAY DETAILS

It is possible to inform RIQAS of your chosen parameters and assay details by

- 1) Completing the 'REGISTRATION OF ASSAY DETAILS' on the following pages **OR**
- 2) Adding your own assay details using RIQASNet

Please select one of the following options

☐

**I wish to add my own assay details via RIQASNet once I have received my username, password and Lab Reference Number from RIQAS**

(You do not need to complete the 'REGISTRATION OF ASSAY DETAILS' section of this document)

☐

**I wish to inform RIQAS of my assay details using this enrolment document**

(please complete all remaining pages of the 'REGISTRATION OF ASSAY DETAILS' section)

For any further queries, please contact your local Randox office, Sales Representative or RIQAS directly.

This programme is accredited by UKAS TO  
ISO/IEC 17043:2010 via Fixed Scope

Please contact RIQAS at

Tel: +44 (0) 28 9445 4399

E-Mail: mail@riqas.com

RIQAS Scheme Co-ordinator: Sarah Fleck

RANDOX LABORATORIES LTD., 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom



0010

## RIQAS THERAPEUTIC DRUGS PROGRAMME

### REGISTRATION OF ASSAY DETAILS

ONLY COMPLETE THIS SECTION IF YOU DO NOT INTEND TO REGISTER  
YOUR METHODS VIA RIQASNET

Please indicate your requirements by ✓ or by writing in the boxes below.  
Current participants should complete the document only for method changes.  
Please state 2-digit Vitros Slide Generation Numbers where appropriate.

| ANALYTE          | METHOD CODE                               | INSTRUMENT                                | REAGENT                                   | SI UNITS | ✓                        | OTHER UNITS                               |
|------------------|---|---|---|----------|--------------------------|---|
| AMIKACIN         | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| CAFFEINE         | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| CARBAMAZEPINE    | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | <input style="width: 100%;" type="text"/> |   |   |          |                          |   |
| CICLOSPORIN      | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | nmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| DIGOXIN          | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | nmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| ETHOSUXIMIDE     | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  |   |   |   |          |                          |   |
| GENTAMICIN       | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| LITHIUM          | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | mmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| OR               |   |   |   |          |                          |   |
| LITHIUM (VITROS) | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | mmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| METHOTREXATE     | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| PARACETAMOL      | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | mmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| (ACETAMINOPHEN)  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| PHENOBARBITAL    | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| PHENYTOIN        | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| PRIMIDONE        | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| SALICYLIC ACID   | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | mmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| THEOPHYLLINE     | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
|                  | VITROS SLIDE GENERATION NO.               |   | <input style="width: 100%;" type="text"/> |          |                          |   |
| TOBRAMYCIN       | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| VALPROIC ACID    | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |
| VANCOMYCIN       | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | <input style="width: 100%;" type="text"/> | µmol/l   | <input type="checkbox"/> | <input style="width: 100%;" type="text"/> |

**Please use this space to describe "other" methods, instruments and reagents.**